High Dose Risankizumab for Psoriasis

Inclusion Criteria: * Subject has provided written consent * Subject has the ability to comply with all study visits and procedures * Subject is at least 18 years of age * Subject has chronic stable plaque psoriasis for at least 6 months and with a severity of BSA greater than or equal to 10 and PASI greater than or equal to 12 * Female subjects of child-bearing potential must have a negative urine test at screening and baseline. Female subjects must be either postmenopausal, or permanently surgically sterile, or for women of child-bearing potential practicing at least one form of birth control Exclusion Criteria: * Breastfeeding or pregnant women, or women who plan to become pregnant during study period * Participation in any other clinical trial * Active infection with HIV, hepatitis B virus, or hepatitis C virus * Active infection with tuberculosis or untreated latent tuberculosis * History of known active cancer, other than non-melanoma skin cancer or cervical carcinoma in situ, in the past 3 years * History of drug or alcohol abuse in the past 6 months, as per investigator's assessment * History of suicidal ideation or attempts in the past 6 months * Presence of any concurrent illness, which in the opinion of the investigator, would place the patient at unnecessary safety risk during the trial or interfere with completion of the trial * Treatment with topical medications for psoriasis in the past 2 weeks * Treatment with oral medications for psoriasis in the past 4 weeks * Phototherapy for psoriasis in the past 4 weeks * Any prior treatment with Risankizumab * Treatment with biologic medications for psoriasis (other than Risankizumab) in the past 4 months